HUTCHMED (NASDAQ:HCM) Shares Gap Up – What’s Next?

HUTCHMED (China) Limited (NASDAQ:HCM)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $14.22, but opened at $15.07. HUTCHMED shares last traded at $15.15, with a volume of 56,261 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Friday, March 21st.

HUTCHMED Stock Performance

The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock’s 50 day moving average price is $14.76 and its two-hundred day moving average price is $16.42.

Institutional Investors Weigh In On HUTCHMED

Hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC increased its holdings in HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after buying an additional 2,255 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of HUTCHMED during the 3rd quarter worth $35,000. Blue Trust Inc. raised its holdings in shares of HUTCHMED by 99.9% during the 4th quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock valued at $102,000 after purchasing an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC lifted its stake in shares of HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock valued at $189,000 after purchasing an additional 1,647 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new position in HUTCHMED during the fourth quarter valued at about $230,000. 8.82% of the stock is owned by hedge funds and other institutional investors.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.